Published in Eur J Nucl Med on June 01, 1998
Procedure guidelines for PET/CT tumour imaging with 68Ga-DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE. Eur J Nucl Med Mol Imaging (2010) 1.68
111In-pentetreotide scintigraphy: procedure guidelines for tumour imaging. Eur J Nucl Med Mol Imaging (2010) 1.03
Impact of sentinel lymph node biopsy in patients with Merkel cell carcinoma: results of a prospective study and review of the literature. Eur J Nucl Med Mol Imaging (2006) 1.03
PET and PET/CT with 68gallium-labeled somatostatin analogues in Non GEP-NETs Tumors. ScientificWorldJournal (2014) 0.81
Are contrast media required for (68)Ga-DOTATOC PET/CT in patients with neuroendocrine tumours of the abdomen? Eur Radiol (2011) 0.80
Guideline for PET/CT imaging of neuroendocrine neoplasms with (68)Ga-DOTA-conjugated somatostatin receptor targeting peptides and (18)F-DOPA. Eur J Nucl Med Mol Imaging (2017) 0.75
Guidelines for radioiodine therapy of differentiated thyroid cancer. Eur J Nucl Med Mol Imaging (2008) 2.67
Axillary lymph node staging in breast cancer by 2-fluoro-2-deoxy-D-glucose-positron emission tomography: clinical evaluation and alternative management. J Natl Cancer Inst (2001) 2.57
Which kinds of lymph node metastases can FDG PET detect? A clinical study in melanoma. J Nucl Med (2000) 1.93
Chromogranin A, neuron specific enolase, carcinoembryonic antigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors. Cancer (1999) 1.54
Radiation dose to technicians per nuclear medicine procedure: comparison between technetium-99m, gallium-67, and iodine-131 radiotracers and fluorine-18 fluorodeoxyglucose. Eur J Nucl Med (1997) 1.42
[The scintigraphy of somatostatin receptors in gastroenteropancreatic neuroendocrine tumors]. Radiol Med (1997) 1.39
How alternative are immunoassay systems employing non-radioisotopic labels? A comparative appraisal of their main analytical characteristics. Q J Nucl Med (1995) 1.39
Positron-emission tomography with [18F]fluorodeoxyglucose. Part I. Biochemical uptake mechanism and its implication for clinical studies. J Cancer Res Clin Oncol (2000) 1.35
Comparison of three different methods for radiolabelling human activated T lymphocytes. Eur J Nucl Med (1997) 1.18
Clinical significance of blood chromogranin A measurement in neuroendocrine tumours. Ann Oncol (2001) 1.17
Joint practice guidelines for radionuclide lymphoscintigraphy for sentinel node localization in oral/oropharyngeal squamous cell carcinoma. Ann Surg Oncol (2009) 1.14
Association between [18F]fluorodeoxyglucose uptake and postoperative histopathology, hormone receptor status, thymidine labelling index and p53 in primary breast cancer: a preliminary observation. Eur J Nucl Med (1998) 1.11
Need, feasibility and convenience of dosimetric treatment planning in liver selective internal radiation therapy with (90)Y microspheres: the experience of the National Tumor Institute of Milan. Q J Nucl Med Mol Imaging (2011) 1.10
The use of standardized uptake values for assessing FDG uptake with PET in oncology: a clinical perspective. Nucl Med Commun (2004) 1.09
A randomized, controlled clinical trial to evaluate the effects of zinc sulfate on cancer patients with taste alterations caused by head and neck irradiation. Cancer (1998) 1.08
Multicenter trial of the quantitative BTA TRAK assay in the detection of bladder cancer. Clin Chem (1999) 1.07
Imaging with 131I-labeled monoclonal antibodies to a high-molecular-weight melanoma-associated antigen in patients with melanoma: efficacy of whole immunoglobulin and its F(ab')2 fragments. Cancer Res (1985) 1.06
Tumour markers CEA, NSE, SCC, TPA and CYFRA 21.1 in resectable non-small cell lung cancer. Anticancer Res (2000) 1.04
Bone scintigraphy and the added value of SPECT (single photon emission tomography) in detecting skeletal lesions. Q J Nucl Med (2001) 1.03
Nuclear medicine imaging of neuroendocrine tumours. Ann Oncol (2001) 1.02
A dosimetric treatment planning strategy in radioembolization of hepatocarcinoma with 90Y glass microspheres. Q J Nucl Med Mol Imaging (2012) 1.01
Comparison of somatostatin receptor imaging, computed tomography and ultrasound in the clinical management of neuroendocrine gastro-entero-pancreatic tumours. Eur J Nucl Med (1998) 0.99
Position of nuclear medicine modalities in the diagnostic work-up of breast cancer. Q J Nucl Med Mol Imaging (2004) 0.98
Efficacy of a chemotherapy combination for the treatment of metastatic neuroendocrine tumours. Ann Oncol (2002) 0.97
Sentinel lymph node mapping and biopsy for breast cancer: a review of the literature relative to 4791 procedures. Tumori (2000) 0.94
Structure, function and gene expression of epithelial mucins. Tumori (1997) 0.93
Prospective evaluation of fluorine-18-FDG PET in presurgical staging of the axilla in breast cancer. J Nucl Med (1998) 0.93
MIBG for diagnosis and therapy of medullary thyroid carcinoma: is there still a role? Q J Nucl Med Mol Imaging (2008) 0.93
Serum and cerebrospinal fluid human chorionic gonadotropin (hCG) and alpha-fetoprotein (AFP) in intracranial germ cell tumors. Int J Biol Markers (2002) 0.89
The objective measurement of remission and progression in metastatic breast cancer by use of serum tumour markers. European Group for Serum Tumour Markers in Breast Cancer. Eur J Cancer (1999) 0.88
The biological characteristics of chromogranin A and its role as a circulating marker in neuroendocrine tumours. Anticancer Res (2000) 0.88
The influence of blood glucose levels on [18F]fluorodeoxyglucose (FDG) uptake in cancer: a PET study in liver metastases from colorectal carcinomas. Tumori (1997) 0.88
(131)I-MIBG treatment of pheochromocytoma: low versus intermediate activity regimens of therapy. Q J Nucl Med Mol Imaging (2010) 0.88
Position of nuclear medicine techniques in the diagnostic work-up of neuroendocrine tumors. Q J Nucl Med Mol Imaging (2004) 0.87
Pattern of mucin gene expression in normal and neoplastic lung tissues. Anticancer Res (1996) 0.87
Accuracy and clinical correlates of two different methods for chromogranin A assay in neuroendocrine tumors. Int J Biol Markers (2005) 0.87
Differences in hippocampal metabolism between amnestic and non-amnestic MCI subjects: automated FDG-PET image analysis. Q J Nucl Med Mol Imaging (2009) 0.86
Osteoprotegerin and osteopontin serum values in postmenopausal advanced breast cancer patients treated with anastrozole. Endocr Relat Cancer (2004) 0.86
Cytokeratin 19 fragment CYFRA 21-1 compared with carcinoembryonic antigen, squamous cell carcinoma antigen and neuron-specific enolase in lung cancer. Results of an international multicentre study. Eur J Clin Chem Clin Biochem (1994) 0.86
Circulating tumor markers in breast cancer (review). Anticancer Res (1990) 0.85
Single-dose intraperitoneal radioimmunotherapy with the murine monoclonal antibody I-131 MOv18: clinical results in patients with minimal residual disease of ovarian cancer. Eur J Cancer (1995) 0.85
Clinical profile of a new monoclonal antibody-based immunoassay for tissue polypeptide antigen. Int J Biol Markers (1995) 0.85
The role of bone SPET study in diagnosis of single vertebral metastases. Anticancer Res (2000) 0.85
Immunosuppressive factors: role in cancer development and progression. Int J Biol Markers (1999) 0.84
Preoperative CEA, NSE, SCC, TPA and CYFRA 21.1 serum levels as prognostic indicators in resected non-small cell lung cancer. Int J Biol Markers (1999) 0.84
(99m)Tc-DTPA uptake in clear-cell renal carcinoma metastases. Rev Esp Med Nucl Imagen Mol (2012) 0.83
Biological activity of anastrozole in postmenopausal patients with advanced breast cancer: effects on estrogens and bone metabolism. Ann Oncol (2002) 0.83
Role of 131I-metaiodobenzylguanidine (MIBG) in the treatment of neuroendocrine tumours. Experience of the National Cancer Institute of Milan. Q J Nucl Med (2000) 0.82
Radioimmunodetection of melanoma: preliminary results of a prospective study. Int J Biol Markers (1988) 0.82
Bone scintigraphy in breast cancer: a ten-year follow-up study. J Nucl Biol Med (1993) 0.82
Results and potential of somatostatin receptor imaging in gastroenteropancreatic tract tumours. Q J Nucl Med (2000) 0.82
A practical dead time correction method in planar activity quantification for dosimetry during radionuclide therapy. Q J Nucl Med Mol Imaging (2009) 0.81
Chromogranin A measurement in neuroendocrine tumors. Int J Biol Markers (1998) 0.81
Myocardial involvement in systemic sclerosis. Rheumatology (Oxford) (2008) 0.81
Immunoscintigraphy of colorectal carcinoma with F (ab')2 fragments of anti-CEA monoclonal antibody. Cancer Detect Prev (1987) 0.81
Axillary lymph node metastases detection with nuclear medicine approaches in patients with newly diagnosed breast cancer. Int J Oncol (1996) 0.81
p53 evaluation in gastric mucosa of patients with chronic Helicobacter pylori infection. Anticancer Res (2001) 0.81
Diagnostic and prognostic tumor markers in the gastrointestinal tract. Semin Surg Oncol (2001) 0.81
Treatment with tandem [(90)Y]DOTA-TATE and [(177)Lu] DOTA-TATE of neuroendocrine tumors refractory to conventional therapy: preliminary results. Q J Nucl Med Mol Imaging (2010) 0.81
Clinical relevance of serological markers in the detection and follow-up of pancreatic adenocarcinoma. Surg Oncol (1996) 0.81
Premenopausal breast cancer patients treated with a gonadotropin-releasing hormone analog alone or in combination with an aromatase inhibitor: a comparative endocrine study. Anticancer Res (1999) 0.81
Assessment of mediastinal involvement in lung cancer with technetium-99m-sestamibi SPECT. J Nucl Med (1996) 0.81
False-negative sentinel node in patients with vulvar cancer: a case study. Int J Gynecol Cancer (2003) 0.81
A simple and semi-automated system for increasing the recovery of aqueous [18F] fluoride from target. Anticancer Res (1998) 0.81
Absorbed dose and biologically effective dose in patients with high-risk non-Hodgkin's lymphoma treated with high-activity myeloablative 90Y-ibritumomab tiuxetan (Zevalin). Eur J Nucl Med Mol Imaging (2009) 0.80
Imaging of neuroendocrine gastro-entero-pancreatic tumours using radiolabelled somatostatin analogues. Ital J Gastroenterol Hepatol (1999) 0.80
Biochemical characteristics and clinical applications of alpha-fetoprotein isoforms. Anticancer Res (1995) 0.80
Radiolabeled somatostaitin analogs in the treatment of neuroendocrine tumors: experience of the National Cancer Institute of Milano using high dose of 111In-pentetreotide in metastatic neuroendocrine gastroenteropancreatic tumors. J Endocrinol Invest (2003) 0.80
Selective axillary dissection after axillary reverse mapping to prevent breast-cancer-related lymphoedema. Eur J Surg Oncol (2013) 0.80
[External exposure of hot cell operators in nuclear medicine]. Radiol Med (1998) 0.80
Neuron-specific enolase evaluation in patients with neuroblastoma. Tumour Biol (1998) 0.79
Individualized dosimetry in the management of metastatic differentiated thyroid cancer. Q J Nucl Med Mol Imaging (2009) 0.79
Imaging of neuroendocrine tumours with gamma-emitting radiopharmaceuticals. Q J Nucl Med Mol Imaging (2010) 0.79
Imaging cancer using single photon techniques. Q J Nucl Med Mol Imaging (2005) 0.79
Anatomical and biochemical investigation of primary brain tumours. Eur J Nucl Med (2001) 0.79
Comparison of gallium scan, computed tomography, and magnetic resonance in patients with mediastinal Hodgkin's disease. Ann Oncol (1997) 0.78
Applications of PET imaging with radiolabelled choline (11C/18F-choline). Q J Nucl Med Mol Imaging (2015) 0.78
Isolated pelvic perfusion for the treatment of unresectable primary or recurrent rectal cancer. Tumori (1997) 0.78
S100 protein serum levels in cutaneous malignant melanoma. Oncol Rep (1998) 0.78
Vertebrobasilar recording with contrast transcranial Doppler in right-to-left shunt diagnosis. Cerebrovasc Dis (2008) 0.78
Short-term effects of anastrozole treatment on insulin-like growth factor system in postmenopausal advanced breast cancer patients. J Steroid Biochem Mol Biol (2002) 0.78
Comparative evaluation of two methods to assay thyroglobulin serum concentrations in patients with differentiated thyroid carcinomas. Q J Nucl Med Mol Imaging (2004) 0.78
Cancer of the uterine cervix: clinical value of squamous cell carcinoma antigen (SCC) measurements. Anticancer Res (1997) 0.78
Dementia with Lewy bodies with supranuclear gaze palsy: a matter of diagnosis. Neurol Sci (2005) 0.78
Treatment with tandem [90Y]DOTA-TATE and [177Lu]DOTA-TATE of neuroendocrine tumours refractory to conventional therapy. Eur J Nucl Med Mol Imaging (2014) 0.78
Orchiectomy alone in clinical stage I nonseminomatous testis cancer: a critical appraisal. J Clin Oncol (1986) 0.78
Accuracy evaluation of fusion of CT, MR, and spect images using commercially available software packages (SRS PLATO and IFS). Int J Radiat Oncol Biol Phys (1999) 0.78
The breast cancer cell line MCF7 as a model of 99mTc-SestaMIBI, 99mTc-tetrofosmin and 99mTc-Medronate incorporation. Anticancer Res (1999) 0.77
Iodine-131 metaiodobenzylguanidine (I-131 MIBG) diagnosis and therapy of pheochromocytoma and paraganglioma: current problems, critical issues and presentation of a sample case. Q J Nucl Med Mol Imaging (2013) 0.77
Applications of 99mTc-sestamibi in oncology. Tumori (1996) 0.77
Preliminary study on oncogene product immunohistochemistry (c-erbB-2, c-myc, ras p21, EGFR) in breast pathology. Int J Biol Markers (1992) 0.77
Short-term effects of pamidronate on bone turnover: can bone markers be considered predictive of the analgesic response? Oncol Rep (2007) 0.77
Diagnostic and therapeutic use of MIBG in pheochromocytoma and paraganglioma. Q J Nucl Med Mol Imaging (2013) 0.77
Evaluation of the soluble fragments of cytokeratin 19 (CK19) in non-small cell lung cancer (NSCLC). Oncol Rep (1996) 0.77
Treatment of recurrent sarcoma of the extremities by isolated limb perfusion using tumor necrosis factor alpha and melphalan. Tumori (1997) 0.76
Circulating tumor markers and nuclear medicine imaging modalities: breast, prostate and ovarian cancer. Q J Nucl Med (2002) 0.76
Molecular imaging: seeing the invisible beyond the "hot spot". Q J Nucl Med Mol Imaging (2004) 0.76
The widened use of exogenous stimulation with recombinant human TSH to treat metastatic thyroid carcinoma in Italy. Q J Nucl Med Mol Imaging (2012) 0.76